GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Mural Oncology PLC (NAS:MURA) » Definitions » Capex-to-Operating-Cash-Flow

MURA (Mural Oncology) Capex-to-Operating-Cash-Flow : 0.00 (As of Sep. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Mural Oncology Capex-to-Operating-Cash-Flow?

Capex-to-Operating-Cash-Flow assesses how much of a company’s cash flow from operations is being devoted to capital expenditure. It’s also useful to distinguish whether the company is capital intensive or not.

Mural Oncology's Capital Expenditure for the three months ended in Sep. 2024 was $-0.01 Mil. Its Cash Flow from Operations for the three months ended in Sep. 2024 was $-30.08 Mil.

GuruFocus do not calculate Capex-to-Operating-Cash-Flow if the Cash Flow from Operations is negative.


Mural Oncology Capex-to-Operating-Cash-Flow Historical Data

The historical data trend for Mural Oncology's Capex-to-Operating-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mural Oncology Capex-to-Operating-Cash-Flow Chart

Mural Oncology Annual Data
Trend Dec21 Dec22 Dec23
Capex-to-Operating-Cash-Flow
- - -

Mural Oncology Quarterly Data
Dec21 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Capex-to-Operating-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Mural Oncology's Capex-to-Operating-Cash-Flow

For the Biotechnology subindustry, Mural Oncology's Capex-to-Operating-Cash-Flow, along with its competitors' market caps and Capex-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Mural Oncology's Capex-to-Operating-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Mural Oncology's Capex-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Mural Oncology's Capex-to-Operating-Cash-Flow falls into.



Mural Oncology Capex-to-Operating-Cash-Flow Calculation

Mural Oncology's Capex-to-Operating-Cash-Flow for the fiscal year that ended in Dec. 2023 is calculated as

Capex-to-Operating-Cash-Flow=- Capital Expenditure / Cash Flow from Operations
=- (-3.452) / -194.249
=N/A

Mural Oncology's Capex-to-Operating-Cash-Flow for the quarter that ended in Sep. 2024 is calculated as

Capex-to-Operating-Cash-Flow=- Capital Expenditure / Cash Flow from Operations
=- (-0.014) / -30.078
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Mural Oncology  (NAS:MURA) Capex-to-Operating-Cash-Flow Explanation

Capex-to-Operating-Cash-Flow ratio assesses how much of a company’s Cash Flow from Operations is being devoted to Capital Expenditure. It is a good indicator in terms of how much the company is focused on growth. In general, a high Capex-to-Operating-Cash-Flow ratio indicates that the company is investing more in physical assets and is focused on growth and expansion. Conversely, lower ratio could indicate that a company has reached maturity and is no longer pursuing aggressive growth.

Moreover, the ratio is also useful to distinguish whether the company is capital intensive or not. If the ratio is large, then the company tends to be capital intensive. Lower ratio suggests that it’s a capital-light business. The ratio can be combined with ROIC % to identify whether the company is an asset-light business that has a high return on invested capital. This is one question investors commonly ask to see if a company qualifies as a good company.


Mural Oncology Capex-to-Operating-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Mural Oncology's Capex-to-Operating-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


Mural Oncology Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
10 Earlsfort Terrace, Dublin 2, Dublin, IRL, D02 T380
Mural Oncology PLC is a clinical-stage oncology company whose entire business is focused on discovering and developing immunotherapies that may meaningfully improve the lives of patients with cancer. By leveraging its core competencies in immune cell modulation and protein engineering, It has developed a portfolio of novel, investigational cytokine therapies designed to address areas of unmet need for patients with a variety of cancers. Its product candidate, Nemvaleukin is an investigational, engineered interleukin-2 cytokine designed to capture and expand the therapeutic benefits of high-dose recombinant human IL-2 while mitigating its hallmark toxicities.